We describe here the synthesis and evaluation of a series of tetrahydroisoquinolines that show subunit-selective potentiation of NMDA receptors containing the GluN2C or GluN2D subunits. Bischler−Napieralski conditions were employed in the key step for the conversion of acyclic amides to the corresponding tetrahydroisoquinoline-containing analogs. Compounds were evaluated using both two-electrode voltage clamp recordings from Xenopus laevis oocytes and imaging of mammalian BHK cells loaded with Ca 2+ -sensitive dyes. The most potent analogues had EC 50 values of 300 nM and showed over 2-fold potentiation of the response to maximally effective concentrations of glutamate and glycine but had no effect on responses from NMDA receptors containing the GluN2A or GluN2B subunits AMPA, kainate, and GABA or glycine receptors or a variety of other potential targets. These compounds represent a potent class of small molecule subunit-selective potentiators of NMDA receptors.
■ INTRODUCTION
The ionotropic family of glutamate receptors comprises Nmethyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptor subtypes, subdivided on the basis of amino acid sequence homology, structure homology, and pharmacology. The NMDA receptor mediates a slow, Ca 2+ -permeable component of excitatory synaptic transmission in the central nervous system and plays a prominent role in normal brain processes, such as learning, memory, synaptic plasticity, and neuronal development. 1−8 In addition, dysfunction of NMDA receptors, either overactivation or hypofunction, has been implicated as a contributing factor to a wide range of neurological disorders, including schizophrenia; 9−11 Alzheimer's disease; 12 Parkinson's disease; 13 Huntington's chorea; 14 depression; 15, 16 epilepsy; 6 neuropathic pain; 17 and acute brain injury following ischemia, 18−20 hypoxia, or trauma. 8, 21 NMDA receptors are ligand-gated cation channels that are tetramers of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits. There are four different GluN2 subunits (GluN2A-D), each of which endows the receptor with unique open probability, single channel conductance, and deactivation time course. 22, 23 For example, GluN2C-and GluN2D-containing NMDA receptors have a lower open probability 24−26 and decreased sensitivity to block by Mg 2+27 and can be activated by lower concentrations of glycine and glutamate than GluN2A-and GluN2B-containing receptors. 28, 29 The four different subunits are differentially expressed throughout the brain, with particularly prominent GluN2C and GluN2D expression in the cerebellum, basal ganglia, and cortical and hippocampal interneurons. 30−32 The distinct localized expression and the unique functional properties of each of the four subunits, along with the potential involvement of NMDA receptors in disease states and injuries, creates a compelling rationale for development of subunitselective modulators with potential use in a variety of neuropathological conditions. Compounds that increase the strength of glutamatergic synapses have been hypothesized to be therapeutically useful in treating schizophrenia. 33−35 For examples, agonists at the GluN1 subunit, for example, glycine and D-serine, have received attention as potential therapies for schizophrenia; 36 however, these molecules will increase the activity of all NMDA receptor subtypes to a similar degree and have activity at other cell-surface receptors expressed in the CNS. 37 By contrast, small molecules directly potentiating the NMDA receptor at regions other than the agonist binding site might exhibit advantageous subunit selectivity and be more selective for the NMDA receptor over other receptors. 38 Moreover the GluN2C and GluN2D subunits are particularly interesting targets in this context because they are expressed on hippocampal and cortical interneurons, 27 whose hypofunction is thought to cause disinhibition of pyramidal cells, leading to excessive drive of the dopaminergic system. 35, 39, 40 Each NMDA receptor subunit contains four semiautonomous domains: an extracellular amino-terminal domain (ATD), an extracellular ligand binding domain (LBD), a transmembrane domain that contributes to the ion conduction pore, and an intracellular carboxy terminus. The binding sites for at least six classes of antagonists of the NMDA receptor are known. Voltage-dependent channel blockers, typically rigid organic cations such as phencyclidine (PCP), bind deep within the ion conduction pore in a voltage-dependent fashion. 41−43 Two additional classes of NMDA receptor antagonists include competitive antagonists that bind with high affinity to either the glycine site on the GluN1 subunit or the glutamate site on the GluN2 subunit. 44−47 A fourth class of noncompetitive antagonists, which includes quinazoline-4-ones and dihydroquinoline-pyrazolines, act at the membrane-proximal portion of the ligand binding domain and are more potent after glutamate but not glycine binding. 48−50 A fifth class of NMDA receptor antagonists binds to the weakly conserved ATD and is highly selective for the GluN2B subunit. 51 Antagonists in this class, which include ifenprodil and a wide range of related structures, show well over 200-fold selectivity for GluN2B over GluN2A, GluN2C, and GluN2D. Finally, a sixth class of antagonists selectively inhibits GluN2A-containing receptors through actions at the dimer interface between the GluN1 and GluN2 ligand binding domains. These compounds, typified by TCN201, are allosteric regulators of glycine binding. 52, 53 In addition to these six classes, several phenanthroic acid and napthoic acid analogues are noncompetitive antagonists that act outside the ATD. 54, 55 In contrast to NMDA receptor antagonists, relatively few compounds have been shown to potentiate NMDA receptor function. Polyamines (e.g., spermine), 56−58 aminoglycosides, 59 and sulfated neurosteroids 60 can enhance the function of GluN2B-containing NMDA receptors with EC 50 values in the range of 40−130 μM. Phenanthroic acid and napthoic acid derivatives increase the current response of GluN2A-and GluN2B-containing receptors at concentrations around 100 μM. 61, 62 In addition, D-cycloserine binds the GluN1 subunit and is a partial agonist at GluN2A, GluN2B, or GluN2D receptors, but can activate GluN2C-containing receptors to a greater extent than glycine. 63, 64 Thus, the few potentiators that are known show strong GluN2 subunit dependence, suggesting potentiation of NMDA receptors is mediated by less conserved portions of the receptor.
To identify small drug-like subunit-selective modulators of NMDA receptors, we previously employed a reverse chemical genetics approach utilizing a fluorescence Ca 2+ imaging-based screen of a diversity library containing 100 000 compounds on BHK cell lines expressing GluN1/GluN2C or GluN1/GluN2D receptors. 65, 66 We identified an NMDA receptor potentiator with micromolar potency that selectively enhanced the function of both GluN2C-and GluN2D-containing NMDA receptors but was without action on GluN2A-and GluN2B-containing receptors. This compound, (6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)-methanone), had a tetrahydroisoquinoline backbone (1) . Compound 1 enhanced the response of GluN2C/D-containing NMDA receptors by 1.5 -fold in the presence of maximally effective concentrations of coagonists glutamate and glycine with an EC 50 value estimated to be 12 μM, but the solubility limit prevented accurate determination of the maximal effect. Compound 1 and related analogues had no agonist activity on their own. We recently described the mechanism and site of action of a related compound, 3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone (2, also referred to as CIQ), which had a reported EC 50 value of 3 μM and enhanced receptor responses less than 2-fold. 66 In this study, we report synthetic efforts toward the optimization of substituents on the core structure of 2 that have led to the development of a structure−activity relationship (SAR) for this class of compounds. 67 The active compounds in this class selectively potentiated current response from GluN2C-and GluN2D-containing receptors. While the core backbone of these compounds is similar to that of the previously identified GluN2B-selective antagonist, HON0001 (3, Figure 1 ), 68 none of the compounds studied here inhibit GluN2B at relevant concentrations. Moreover, this class of compounds did not affect responses from GluN2A-containing receptors or from GluA1 AMPA receptors and GluK2 kainate receptors, suggesting this class of compounds shows strong subunit selectivity.
■ RESULTS

Chemistry.
To explore the SAR of the tetrahydroisoquinoline compound class as posititve allosteric modulators of GluN2C/2D-containing NMDA receptors, a series of derviatives were synthesized. For SAR development, the core tetrahydroisoquinoline was divided into three modifiable rings (A, B, and C) and two modifiable linker regions (linker A and linker B) ( Figure 2) . Compounds 5, 6 , and 7 were synthesized from 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (4) and the corresponding benzoyl chloride (Scheme 1). All other synthetically derived analogues were generated via one of three pathways, each starting with substituted phenethylamines. 2-(3-(Benzyloxy)phenyl)ethanamine (12) was prepared from 3-methoxyphenethylamine (8) in the sequence shown in Scheme 2. The starting material (8) was demethylated in a refluxing mixture of acetic acid and hydrobromic acid to form the phenol 9. The primary amine was then Boc-protected to form 10 followed by an alkylation of the phenol with benzyl bromide to give 11. The Boc group was removed under acidic conditions to give the phenethylamine 12.
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The synthesis scheme employed for the preparation of each analogue was dependent upon the identity of the linker between the tetrahydroisoquinoline core and the B ring ( Figure  2 ). For compounds containing an ether or thioether linker, an appropriately substituted phenethylamine (8, 12−18) was acylated with chloroacetyl chloride to afford the α-chloroamide-containing compounds 19−26. Displacement of the chlorine with a phenol or thiophenol in the presence of base afforded 27−42 and 43, respectively. The amides 27−43 were then subjected to Bischler−Napieralski conditions to form the dihydroisoquinolines (45−62) . The nitro-containing amide compound 42 was subjected to hydrogenolysis, followed by a reductive amination to afford the dimethylamino-containing intermediate, which was then cyclized using Bischler− Napieralski conditions to give the dihydroisoquinoline 44 . The dihydroisoqunolines were subsequently reduced with sodium borohydride (NaBH 4 ) to afford the racemic tetrahydroisoquinolines 63−80. Acylation of 63−80 with a substituted benzoyl chloride afforded analogues 2 and 81−127 (Scheme 3). Nitro-containing analogues 128−130 were reduced to the corresponding anilines (131−133) with tin(II) chloride dehydrate. 69 The anilines (131−133) were then subjected to reductive amination conditions to give the methylaminocontaining analogues 134 and 135. 69, 70 Although the A-ring in each of the compounds described above is a substituted phenyl ring, a number of compounds were synthesized with various aromatic or heterocyclic moieties in place of the phenyl. These compounds were synthesized in one step from tetrahydroisoquinoline 63 in an acylation reaction with an aryl chloride or 4-morpholinyl chloride (Scheme 4). In addition, tetrahydroisoquinoline 63 was acylated with chloroacetyl chloride, followed by chlorine displacement with morpholine to afford 23, with a modified A-ring and linker A. Tetrahydroisoquinoline 63 was also subjected to alkylation conditions to form the tertiary amine 141 (Scheme 4).
In addition, compounds with either a saturated or an unsaturated carbon linker, a substituted cinnamic acid, or phenylpropionic acid underwent standard EDC-coupling conditions with a substituted phenethylamine (8 or 13) to afford amides 142−145. Amides 142−145 were then subjected to Bischler−Napieralski conditions in refluxing POCl 3 to afford the corresponding dihydroisoquinolines (146−149), which were subsequently reduced with NaBH 4 to afford the tetrahydroisoquinolines 150−153. Acylation of 150−153 with a series of substituted benzoyl chlorides afforded the final analogues 154−162 (Scheme 5). Compounds with a shorter linker than those described above were synthesized according to the procedure shown in Scheme 6. The commercially available phenylacetic acids (163 and 164) were each treated with thionyl chloride to form the corresponding acid chlorides, which were subsequently reacted with 3,4-dimethoxyphenethylamine (13) to give amides 165 and 166. The amides were then subjected to Bischler−Napieralski reaction conditions to form the dihydroisoquinoline intermediates (167 and 168), which were further reduced to the tetrahydroisoquinolines (169 and 170) with sodium borohydride. The core was then acylated with an appropriately substituted benzoyl chloride to afford final compounds 171−175.
Stereoselective Synthesis of Compound 2. The stereoisomers for 2 were synthesized according to the procedure shown in Scheme 7. Either enantiomer of the commercially available chiral amine (177) was subjected to acylation conditions with 3,4-dimethoxyphenylacetyl chloride (176), to give the secondary amide 178. Reduction of the amide with borane dimethylsulfide complex and boron trifluoride etherate gave the corresponding amine (179) in excellent yields. 71 Acylation with chloroacetyl chloride followed by halogen displacement with 4-methoxyphenol afforded the tertiary amide (181). Treatment of amide 181 with phosphorus oxychloride afforded the chiral iminium intermediate, which was subsequently reduced to the tetrahydroisoquinoline (182) with sodium borohydride. Although crystallographic data will be needed to confirm the assignment, the stereochemistry of the reduction has been assigned on the basis of the model shown in Figure 3 and the literature precedent for the use of this chiral directing group in similar reductions. 72−74 Tetrahydroisoquinoline 182 was subjected to hydrogenolysis to remove the chiral directing group, followed by acylation with 3-chlorobenzoyl chloride, to give the assigned R-(+) and S-(-) enantiomers of 2.
Potentiation of NMDA Receptors. All of the compounds synthesized, in addition to 33 commercially available analogues (184−217), were evaluated using two-electrode voltage clamp recordings of currents from four recombinant NMDA receptor subtypes: GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C, and GluN1/GluN2D. We initially evaluated the conditions under which to best assess compound activity. At low concentrations of agonist (0.3 μM glutamate, 0.1 μM glycine), compound 2 produced strong potentiation (353 ± 36% of control at 10 μM for GluN2D), but full concentration effect curves could not be fitted with the Hill equation, limiting our ability to obtain EC 50 values with which to compare analogues. By contrast, concentration effect curves for compound 2 recorded in response to maximally effective concentrations of glutamate (100 μM) and glycine (30 μM) were well-fitted by the Hill equation (maximum 228 ± 8.8% of control for GluN2D). For all subsequent experiments, concentration− response curves for each compound were generated by coapplying increasing concentrations of compound with maximally effective concentrations of glutamate and glycine. Each compound was tested in at least five oocytes from two different frogs. The mean degree of potentiation measured at 10 μM for each compound at GluN1/GluN2C and GluN1/ GluN2D is presented in Tables 1−9 . For compounds exhibiting more than 115% potentiation at 10 μM, the EC 50 values were determined by fitting composite concentration−response curves to eq 1 ( Tables 1−9) . None of the compounds tested potentiated responses from receptors comprised of GluN1/ GluN2A or GluN1/GluN2B, and thus, these data are not shown. A small subset of compounds produced weak inhibition (70% of the control response at 100 μM) of GluN1/GluN2A (compounds 7, 84, 110, 186) or GluN1/GluN2B (compounds 1, 96, 100, 101, 109, 139, 192, 206) ; these inhibitory effects were not studied further.
In addition, several active compounds were tested against a representative member of the AMPA-selective class of glutamate receptors (GluA1) and of the kainate-selective glutamate receptor class (GluK2 Compounds 1, 2, 190 , and 197 were coapplied with 100 μM glutamate to GluK2-expressing oocytes and had no effect on GluK2-mediated currents. Compound 83 was tested on an additional 19 receptors (e.g., AMPA, GABA, glycine, nicotinic acetylcholine, purinergic) using the oocyte expression system (see below). Together, these results suggest strong GluN2C/D selectivity for this series of compounds.
Effect of Removing Linker B and the B-Ring. To determine the importance of each portion of the compound for potency, fragments of the lead compound 1 and two lead compounds, 2 and 192, were synthesized and tested. Compounds 5, 6, and 7 correspond to compounds 1, 2, and 190 without the linker B and the B-ring ( Figure 4 ). All three of these compounds were inactive against all recombinant NMDA receptors (n = 6−10 oocytes for GluN1/GluN2A, GluN1/ GluN2B, GluN1/GluN2C, and GluN1/GluN2D; data not shown). Reducing the length of the linker to a single methylene also removed all activity (171−175 in Figure 4 ; data not shown). Thus, the B-ring and the two-atom linker are essential for activity in this series.
Optimization of A-and B-Ring Substituent Position. We evaluated the optimal placement of substituents on the Aring (Table 1) . Substituents in the 3-position, (R 3 in Table 1) showed the strongest potentiation compared with substitution in the 2-(R 4 ) or 4-(R 2 ) position. This is evident when comparing potentiation associated with the methyl-containing analogues 184, 185, and 186. For this subset of compounds, 185, with a methyl in the 3-position (R 3 , Table 1 ), is the most effective and potentiates GluN2C-and GluN2D-containing receptors to a greater extent. When a chlorine substituent was placed on the A-ring, as in compounds 187, 2, and 188, the 3-chloro analogue (2) showed greater potentiation compared with the 2-and 4-chloro derivatives (187, 188; Table 1 ). Analogues with dichloro (86, 85, 194, 87) or 3-chloro-4-fluoro (88) substitutions on the A-ring showed EC 50 values (when active) ranging from 1.4to 21 μM on GluN2C and from 1.9 to 24 μM on GluN2D (Table 1) .
We also evaluated the positional effects of B-ring substitutions. Data in Table 2 show that the para position (R 2 , Table 2 ) on the B-ring is the only position that affords any detectable activity for methoxy substituents. When a methoxy substituent is placed in either the ortho or meta position, all activity is lost ( Table 2) .
Optimization of Substituent Identity on A-and BRings. Since substitution in the meta position on the A-ring yielded the most potent and effective potentiators, a number of modifications were made to this position (R 1 in Table 3) . Substitution on the A-ring with 3-bromo (190), 3-iodo (93), and 3-trifluoromethyl (198) gave strong potentiation with potencies similar to compound 2. 66 All other substitutions on the 3-position on the A-ring showed either a decreased potency or a decreased maximum degree of potentiation. These data suggest that the binding pocket has both size and electronic requirements. Since 2 and 190 show similar potencies and maximal effects and they are more active than the 3-fluoro (197) analogue, it was expected that the 3-iodo (93) analogue would be active. Although not as potent as the 3-bromo (190) derivative, the 3-iodo (93) analogue showed enhanced maximal potentiation. Interestingly, addition of a similarly large phenyl (94) ring shows reasonable potency but a diminished degree of potentiation. In addition, when R 3 is an electron-withdrawing group, such as nitro (84), the compounds are less potent but more efficacious (Table 3) . Figure 5A summarizes optimal substitutions on the A-ring. We subsequently evaluated a range of different ring systems in place of ring A (Table 4) . Only 2-thiophene (203) showed weak activity at GluN2C-containing receptors with no or minimal potentiating effects at GluN2D-containing receptors. The weak selectivity of this ring system for GluN2C suggests a possible starting point from which to develop future compounds with selectivity for GluN2C over GluN2D.
As shown in Table 2 , only compounds with a para substitution pattern around the B-ring have detectable potentiation on recombinant GluN2C/GluN2D receptors. 
Scheme 7
a a (a) NaOH, DCM/H 2 O, R = 72%, S = 82%; (b) BF 3 ·OEt 2 O, then BH 3 ·THF, THF, R = 90%, S = 95%; (c) 2-chloroacetyl chloride, Et 3 N, DCM, R = 80%, S = 73%; (d) 4-methoxyphenol, Cs 2 CO 3 , MeCN, R = 74%, S = 73%; (e) POCl 3 , toluene, reflux; (f) NaBH 4 , MeOH, −78°C, R,R = 34%, S,S = 34%; (g) H 2 , Pd/C, EtOH; (h) 3-chlorobenzoyl chloride, Et 3 N, DCM, R = 51%, S = 34%. Several modifications were made to the para position substituent on the B-ring to test for the optimal functionality in this position (R 2 in Table 5 ). When a thiomethyl is placed in the 4-position, there is potentiation if the analogue also contains a 3-chloro on the A-ring (104), but not a hydrogen (103). The potency of 104 is similar to the 4-methoxycontaining analogue (2) , but the degree of potentiation is reduced. The 4-ethyl analogue is weakly active at GluN2C (207; Table 5 ). A 4-dimethylamino substituent shows potentiation preferentially of GluN2C if the analogue also contains a 3-chloro or 3-bromo on ring-A (107 and 108, respectively), but not a hydrogen (106). Substitution with ethoxy (100, 101), benzyloxy (109), amino (133, 132, 131), or nitro (129, 130, 128) led to compounds with no detectable activity on recombinant GluN2C-or GluN2D-containing receptors. These results suggest that the methyl ether is important for binding. Moreover, steric effects may explain the lack of efficacy for the larger substituents, such as benzyloxy (109; Table 5) .
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Optimization of C-Ring Substitutions. All of the compounds described above contain a dimethoxy substitution pattern on the C-ring (R 3 and R 4 ; Table 6 ). Substitution of methyl groups in place of both methoxy substituents results in modestly enhanced potency (∼1 μM EC 50 ) and increased maximal potentiation (compare 122 and 123 with 2 and 190). When a dioxolane is fused at these two positions (110, 111, 112), the potency is decreased when compared with the dimethoxy analogues (1, 2, 190) . When the R 3 -methoxy is removed and a R 2 -methoxy is installed (Table 6 ), the resulting compounds show modest changes in either potency or maximal effect. Compounds with dimethoxy substitutions at R 4 and R 5 (120 and 121; Table 6 ) are inactive. This suggests that substitution at the R 5 position introduces unfavorable steric interactions within the binding pocket. In addition, the decrease in potency associated with a non-hydrogen substituent at R 2 may be explained by steric interactions between linker B and the substituent at R 2 on the C-ring. Interestingly, when a single methoxy is placed at R 4 on the Cring, as in compounds 116 and 117, potency is increased when compared with the dimethoxy counterparts ( Table 6) . While compound 118 does not show increased potency compared with its dimethoxy analog, it does exhibit a greater maximum potentiation, further suggesting that a single substitution at R 4 on the C-ring is optimal for activity. This trend of increased effectiveness also appears to hold for the methyl-substituted C ring. Compounds 122 and 123 show increased potency compared with 2 and 190, and when a single methyl is placed at R 4 on the C-ring, as in compounds 124, 125, and 126, the maximal effect is slightly increased. Interestingly, introduction of O-benzyl substitutions at the R 4 position results in the most potent compounds tested. Compounds 82 and 83 show submicromolar EC 50 values (0.3−0.4 μM) with strong potentiation of 254−257% at GluN2C and 198−219% at GluN2D, suggesting that space exists within the binding pocket that can be exploited to enhance potency. Figure 5B summarizes optimal substitutions on the C ring.
Optimization of Linker A and Linker B. There are two regions on the backbone that link the 3 rings together: linker A and linker B (Figure 2) . In both the original screening hit (1) and 2, linker A is an amide linkage. As shown in Table 7 , extension of this linker into a urea (211, 212) or thiourea (211, 212, 213, 214, and 215) leads to a loss of activity for all but one analogue (215), which retained only weak potentiating activity ( Table 7) . Substitution of the amide with a sulfonamide (216, 217) eliminated all activity on GluN1/GluN2C and GluN1/ GluN2D receptors (Table 8) , as did reduction of the amide linkage to a tertiary amine (141; Table 8 ). These data suggest that both the potency and maximal degree of potentiation of this series are dependent on the amide linkage.
All of the compounds described thus far contained an ether linkage in linker B. 5 ), and sigma receptors (σ 1 , σ 2 ) as well as serotonin, dopamine, and norepinephrine transporters (n = 4 for each). The initial screen determined significant inhibition at the κ opioid receptors, which was studied further. Compound 83 inhibited antagonist binding to kappa opioid with K i > 5 μM, 15-fold higher than the EC 50 for NMDA receptor potentiation. The combined data from these off-target screens highlights the remarkable selectivity of this series for GluN2C-and GluN2D-containing receptors.
Potency of Stereoisomers. All compounds in this series thus far have been synthesized and tested as racemic mixtures. We studied the stereoisomers of compound 2 by first separating the two enantiomers using chiral supercritical fluid chromatography (SFC; see Chemistry Experimentals). We assessed the activity of each enantiomer in BHK cells that stably express GluN1/GluN2C or GluN1/GluN2D using the Ca 2+ -sensitive dye Fluo4 and in oocytes expressing GluN1/GluN2C or GluN1/GluN2D using two-electrode voltage clamp recordings. The activity determined in these two assays suggested that one enantiomer potentiates the response of GluN1/GluN2C and GluN1/GluN2D receptors to a far greater extent than the -imaging experiments with BHK cells, the active SFC peak potentiated GluN2C and GluN2D responses with EC 50 values of 7.1 and 6.6 μM, respectively (N = 4). We therefore carried out stereoselective-synthesis of the two enantiomers of compound 2 and directly compared the activity of these two enantiomers using two-electrode voltage clamp recordings. The results suggested that the S-(−) enantiomer (>98% ee) of compound 2 (with stereochemistry assigned on the basis of literature precedent 72−74 ) potentiates the response of GluN2C and GluN2D by 304% and 294% with estimated EC 50 values of 9.0 and 8.0 μM, respectively. Like the racemic form, 2-S-(−) had no effect on GluN2A-or GluN2B-containing receptors. By contrast, the R-(+) enantiomer (90% ee) possessed minimal activity, which was indistinguishable from that predicted for the 5% residual S-(-) enantiomer ( Figure 5C ). These data suggest that the binding pocket preferentially accommodates one enantiomer, and this stereoselectivity may provide a means to further enhance the selectivity of this compound class over other central nervous system targets. Given the limited solubility of compound 2, we attribute the slightly reduced potency of the purified enantiomer (8−9 μM) compared with the racemic mixture (4.6−5.0 μM) to the greater amount of active species in solution for the purified enantiomer compared with a racemic mixture at concentrations near the limit of solubility. The larger amount of the active enantiomer in solution before the solubility limit allows a better estimate of the maximum potentiation, which was higher for the S-(−) isomer (304% and 294% for GluN2C and GluN2D) than for racemic 2 (233% and 215% for GluN2C and GluN2D). The higher potentiation led to increases in EC 50 values compared with racemic mixture.
■ CONCLUSION
Introduction of a single of O-benzyl substitution at the R 4 position of the tetrahydroisoquinoline of compound 2 provided compound 83, a GluN2C-and GluN2D-selective potentiator with 300 nM potency. Moreover, the majority of the activity attributed to the compounds in this class of tetrahydroisoquinoline potentiators appears to arise from a single enantiomer, tentatively assigned with S stereochemistry. This class of potentiators also demonstrates strong selectivity for GluN2C and GluN2D receptors with the most potent analogue showing no activity at over 65 receptors, channels, and transporters expressed in the central nervous system. In addition, compounds 107, 108, 205, and 203 may represent potential starting points for developing GluN2C-selective modulators.
■ BIOLOGY EXPERIMENTALS
Two-electrode voltage-clamp recordings were performed on Xenopus laevis oocytes expressing recombinant rat GluN1/ GluN2A, GluN1/GluN2B, GluN1/GluN2C, GluN1/GluN2D, GluA1, or GluK2 receptors. cDNAs for rat GluN1-1a (GenBank accession numbers U11418 and U08261; hereafter, GluN1), GluN2A (D13211), GluN2B (U11419), GluN2C (M91563), GluN2D (L31611), GluA1 (X17184), GluK2 (Z11548) were provided by Drs. S. Heinemann (Salk Institute), S. Nakanishi (Kyoto University), and P. Seeburg (University of Heidelberg). Oocyte isolation, RNA synthesis, and RNA injection were completed as described in detail elsewhere; 75 all protocols involving X. laevis were approved by the Emory University Institutional Animal Care and Use Committee. During two-electrode voltage-clamp recordings, oocytes were placed into a perfusion chamber and continually washed with recording solution containing (in mM) 90 NaCl, 1.0 KCl, 0.5 BaCl 2 , 0.005 EDTA, and 10 HEPES at pH 7.4 (23 In contrast to 1-naphthyl, higher concentrations of 2-naphthyl did show activity (136 ± 5.5% potentiation of GluN2C at 100 μM).
°C).
Glass electrodes with a tip resistance of 0.3−1.0 MΩ were pulled from thin-walled glass capillary tubes and filled with 3.0 M KCl. An OC-725C amplifier (Warner Instruments) was used to hold the membrane potential of the oocytes at −40 mV during current recording. All compounds were made as 20 mM stock solutions in DMSO and dissolved to reach the desired final concentration in recording solution containing 100 μM glutamate and 30 μM glycine for use on oocytes expressing NMDA receptors. Final DMSO content was 0.05−0.5% (v/v). Oocytes expressing GluK2 receptors were pretreated with 10 μM concanavalin A for 10 min. Recombinant GluA1 and GluK2 receptors were activated by 100 μM glutamate. To prevent a gradual increase in current response over the course of the experiment, which is a common feature of GluN1/ GluN2A receptor responses in oocytes, some oocytes expressing GluN1/GluN2A were either pretreated for 10 min with 50 μM BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester)) or injected with 50 nL of 2 mM K-BAPTA (potassium 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid). For every test compound, we recorded 5−7 concentrations in at least 5 oocytes obtained from two different frogs. We subsequently determined mean potentiation at 10 μM (± SEM), and when potentiation exceeded 115% of control, we determined the EC 50 (half-maximally effective concentration of potentiator) by fitting the equation
( 1) to the average composite concentration−response data normalized to the current in the absence of potentiator (100%). N is the Hill slope, which ranged between 1 and 2 and is not reported; maximum is the maximal response predicted for saturating concentration of potentiator. A few compounds produced modest inhibition (70% of controls at 100 μM); these inhibitory actions were not studied further.
For off-target data, GABA C (ρ1), glycine (α1), serotonin (5-HT 3A ), nicotinic acetylcholine (nAChR, α1β1δγ, α4β2, α3β4, α9α10, α7), and purinergic (P2 X2 rat, P2 X2 human) receptors were expressed in Xenopus oocytes. cRNA encoding the receptor subunits was synthesized from linear template cDNA using the mMessage mMachine kit (Ambion). Oocytes were injected with 1−5 ng cRNA in a 50 nL volume and incubated in Barth's solution at 15°C for 2−5 days prior to recording. α1β1δγ nAChR subunits were injected at a 1:1:1:1 ratio, and α4β2, α3β4, and α9α10 nAChR subunits were injected at a 1:1 ratio. The cDNAs encoding GABA C , glycine, and serotonin subunits were provided by Dr. D. Weiss (University of Texas Health Science Center at San Antonio). cDNAs encoding nicotinic acetylcholine receptor subunits were provided by Drs. R. Papke (University of Florida) and S. Heinemann (Salk Institute). cDNAs encoding the purinergic receptors were provided by Dr. R. Hume (University of Michigan). GABA C receptors were activated by 2 μM GABA. Acetylcholine was used at the indicated concentrations (micromolar) to activate the nicotinic acetylcholine receptors: α1β1δγ (1), α4β2 (10), α3β4 (10), α9β10 (1), and α7(300). Glycine, 50 μM, was used to activate the glycine receptor, 100 μM serotonin was used to activate the 5-HT 3A receptor, and 9 μM ATP was used to activate the purinergic receptors. 76 with the following modifications: One day prior to the experiment, the cells were seeded in 20 μL of media at 600 000 cells/mL in black, clear-bottom, 384-well plates (Corning CellBind). On the day of the experiment, the media was aspirated and replaced with Flou-4 NW (Invitrogen) dissolved in HEPES-buffered saline (HBSS, Gibco no. 14175-053) consisting of (millimolar) 5.33 KCl, 0.441 KH 2 PO 4 , 4.17 NaHCO 3 , 137.9 NaCl, 0.338 Na 2 HPO 4 , 5.56 D-glucose, 2 CaCl 2 , and 20 HEPES (pH 7.4), with 2.5 mM (1%) Probenecid, and 30 μM 7-chlorokynurenic acid for 60 min at 37°C in the dark. Cells were then gently washed with 30 μL/ well using the same buffer without the Flou-4 dye and placed in 20 μL/well buffer. Using a FDSS7000 instrument (Hamamatsu), real time recordings of changes in Fluo-4 emission was performed (excitation 480 nm and emission 540 nm) at room temperature (20−22°C). After 10 s of baseline recordings, 10 μL/well of 3× concentrated test compound, controls, or assay buffer in HBSS (pH 7.4 ) and 1 mM glycine (final concentration) were added. After 2 min, an additional 10 μL/well were added containing 4× concentrated solutions of NMDA (GluN2C, 1000 μM; GluN2D, 300 μM). Changes in fluorescence were recorded for subsequent 2 min. For determination of the concentration−response relationships, test compounds were serial diluted 3-fold over 10 concentration steps. Responses (fluorescence units, FU) were normalized to the first recording and expressed as percent of maximally effective concentration of NMDA (see above). The EC 50 value was determined by nonlinear least-squares fitting of eq 1 to the data.
The maximum solubility (20 μM) was determined for compound 2 using a BMG Labtech Nephelostar nephelometer (Offenburg, Germany), according to the manufacturer's instructions. Only responses for concentrations below the experimentally determined limit of solubility were measured; whenever visual evidence of precipitation at higher concentrations was observed, experiments were repeated with 1−10 mM 2-hydroxypropyl-β-cyclodextrin added to the recording solution to ensure that the compounds remained in solution. 2-Hydroxypropyl-β-cyclodextrin had no detectable effect on NMDA receptor response amplitude (data not shown). We also evaluated the stability of potentiator activity by making a solution of 10 μM 2 and continuously agitating it. After increasing periods of time, some of the solution was filtered (0.2 μm nylon filter) and used to measure the potentiation of GluN1/GluN2D receptors expressed in X. laevis oocytes. Similarly, we tested the concentration−response effects of 2 on maximal responses induced by NMDA on GluN1/GluN2C in BHK cells by measuring changes in fluorescence of Fluo-4 at different time points after making the compound solutions. Activity (potency and efficacy) was retained without loss until 6 h, whereas no activity was seen after 24 h. Results from these two experiments suggested that compound 2 remains active in solution up to 2−3 h, with activity decreasing thereafter until by 24 h, there is no detectable activity. 
The enantiomers of 2 were obtained by supercritical fluid chromatography on a Berger Multigram II operating at 50 mL/ min at 35°C and 100 bar backpressure. The column was a Phenomenex Lux 5u Cellulose-1 (250 × 21.2 mm). The eluent was CO 2 (60%) and methanol +0.1% diethylamine (40%). A 15 mg portion was dissolved in methanol, and 200 stacked injections of 0.4 mL were performed. Enantiomeric excess was determined on an Aurora Fusion A5 SFC system operating at 3 mL/min at 40°C and 100 bar backpressure. The column was a Phenomenex Lux 3u Cellulose-1 (150 × 4.6 mm). The eluent was CO 2 (70%) and ethanol +0.1% diethylamine (30%). The EE of peak 1 (rt 1.584 min) determined at 220 nM was 98.3%; peak 2 (rt 2.708 min), 98.2%.
■ CHEMISTRY EXPERIMENTALS
Compounds not described were purchased from either Life Chemicals All reagents for synthesis were obtained from commercial suppliers and used without further purification. Reaction progress was monitored by thin layer chromatography (TLC) on precoated aluminum plates (silica gel 60 F254, 0.25 mm). Proton and carbon NMR spectra were recorded on an INOVA-400 (400 MHz) or VNMRS 400 (400 MHz). The spectra obtained were referenced to the residual solvent peak. Mass spectra were performed by the Emory University Mass Spectroscopy Center on either a VG 70-S Nier Johnson or JEOL instrument. Elemental analyses were performed by Atlantic Microlab Inc. Purity was established using HPLC, unless indicated by combustion analysis, and were found to be ≥95%. C, H, N agreed with proposed structures ±0.4% of theoretical values unless indicated. Optical activity was measured at 20°C with a Perkin-Elmer model 341 polarimeter. Flash chromatography was performed on a Teldyne ISCO CombiFlash Companion System with prepackaged Teledyne RediSep or Silicycle normal phase columns with silica gel.
General Preparation for 1,2,3,4-Tetrahydroisoquinoline Compounds (Procedure I). 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.0 g, 4.4 mmol) was dissolved in DCM (20 mL) and saturated aqueous sodium bicarbonate solution (20 mL). The biphasic reaction mixture was cooled to 0°C in an ice bath, and benzoyl chloride (3 equiv) was added dropwise. After complete addition, the reaction was warmed to room temperature and stirred for an additional 2 h, when TLC indicated complete conversion. The organics were separated, and the aqueous phase was extracted with DCM (2×). The organics were combined, washed with brine and water, dried over MgSO 4 , filtered, and concentrated in vacuo. The resulting residue was subjected to flash column chromatography.
General Preparation for 2-chloro-N-phenethylacetamide Compounds (Procedure II). A solution of a phenethylamine (1.0 equiv) in DCM was cooled to 0°C in an ice bath. To this solution, Et 3 N (3.0 equiv) was added followed by dropwise addition of an acid chloride (1.2 equiv). Upon complete addition, the reaction was warmed to room temperature and stirred for 2 h. When TLC indicated complete conversion, the reaction mixture was concentrated in vacuo. The resulting residue was taken up into DCM and washed with a saturated solution of NH 4 Cl and brine. The aqueous layer was then extracted with DCM (2×). The organic layers were combined, washed with water, dried over MgSO 4 and filtered. The solvent was removed in vacuo. The resulting solid was subjected to flash column chromatography. General Preparation for N-(Phenethyl)-2-(phenoxy)-acetamide and N-(Phenethyl)-2-(phenyl)thio)acetamide Compounds (Procedure III). To a solution of phenol or thiophenol (7.3 mmol) in MeCN (15 mL) was added Cs 2 CO 3 (3.0 equiv.) at room temperature, and the reaction mixture was allowed to stir for 2 h. A solution of the α-chloroamide (1.2 equiv) dissolved in dry MeCN (15 mL) was added, and the resulting reaction mixture was stirred for 18 h under an argon atmosphere. After TLC indicated complete conversion, the volatiles were removed in vacuo, and the resulting residue was treated with NH 4 Cl and extracted into EtOAc (2×). The resulting organic layer was washed with brine and water, dried over MgSO 4 , filtered, and concentrated in vacuo. The resulting solid was subjected to flash column chromatography.
General Preparation for 3,4-Dihydroisoquinoline Compounds (Procedure IV). To a solution of 3 (3.5 mmol) suspended in toluene (40 mL) was added POCl 3 (3.0 equiv), dropwise. The reaction mixture was brought to reflux and allowed to stir for 90 min before cooling to room temperature. The resulting precipitate was filtered and carried on without further purification.
General Preparation for 3,4-Dihydroisoquinoline Compounds (Procedure V). The amide (1.0 equiv) was dissolved in dry toluene (30 mL) and brought to reflux. Phosphorus pentoxide (7.0 equiv) was added to the refluxing solution over about 15 min. The reaction was refluxed for an additional 30 min. The toluene was decanted, and the remaining residue was dissolved in water and washed with ether (2×). The aqueous solution was treated with NH 4 OH and extracted into DCM (3×). The organic layer was separated, dried over MgSO 4 , filtered and concentrated in vacuo. The crude product was taken on without further purification.
General Preparation for 1,2,3,4-Tetrahydroisoquinoline Compounds (Procedure VI). The dihydroisoquinoline 4 (4.0 mmol) was suspended in anhydrous MeOH (40 mL). The reaction mixture was cooled to 0°C in an ice bath. NaBH 4 (3.0−4.0 equiv) was added slowly to the reaction mixture under an argon atmosphere. It was then allowed to warm to room temperature and stirred for 6 h to overnight, until TLC indicated complete conversion. Volatiles were removed in vacuo. The resulting residue was dissolved in DCM and washed with 1 N HCl, water, and brine. The aqueous layer was extracted with DCM (2×). The organic layers were combined, dried over MgSO 4 and filtered. Volatiles were removed in vacuo. The crude residue was subjected to flash column chromatography.
General Preparation for 3,4-Dihydroisoquinolin-2(1H)-yl)methanone Compounds (Procedure VII). The tetrahydroisoquinoline 5 (1 mmol) was dissolved in anhydrous DCM (10 mL). The solution was cooled to 0°C in an ice bath. Triethylamine (3.0 equiv) was added to the cooled solution, followed by dropwise addition of a benzoyl chloride (1.2 equiv). The reaction mixture was allowed to warm to room temperature and stirred for an additional 90 min. Volatiles were removed in vacuo. The resulting residue was treated with NH 4 Cl saturated solution, followed by extraction with DCM (2×). The organic phase was washed with brine and water, dried over MgSO 4 , filtered, and concentrated to yield a residue. The resulting residue was subjected to column chromatography to afford the final products as a mixture of two rotamers.
General Preparation for 3,4-Dihydroisoquinolin-2(1H)-yl)methanone Compounds (Procedure VIII). Benzoic acid (1.0−1.3 equiv) was dissolved in dry DCM (15 mL) and cooled to 0°C in an ice bath. DMAP (1.2 equiv) and EDC (1.2 equiv) were added, and the reaction was stirred at 0°C for 2 h. Tetrahydroisoquinoline (1.0 equiv) dissolved in DCM (10 mL) was added to the cooled reaction, and it was warmed to room temperature and stirred for an additional 18 h. When TLC indicated complete conversion, 1 M HCl was added, and the aqueous phase was extracted with DCM (2×). The organics were combined and washed with brine and water, dried over MgSO 4 , filtered, and concentrated in vacuo. The resulting residue was subjected to column chromatography to afford the final products as a mixture of two rotamers.
General Preparation of N-(Phenethyl)-3-phenylpropanamide and (E)-N-(Phenethyl)-3-(phenyl)acrylamide Compounds (Procedure IX). Phenylpropionic acid (6.7 mmol, 1.0 equiv) or cinnamic acid (5.6 mmol, 1.0 equiv) was dissolved in dry DCM (20 mL) and DMF (10 mL), and the reaction mixture was brought to 0°C in an ice bath. EDC (1.3 equiv) and DMAP (1.1 equiv) were added, and the reaction mixture was stirred at 0°C for 2 h. 3,4-Dimethoxyphenethylamine (6.7 mmol, 1.0 equiv) was added dropwise. The solution was warmed to room temperature and stirred overnight. After TLC indicated complete conversion, 1 M HCl was added, and the reaction mixture was extracted into DCM (3×). The organics were combined, washed with brine and water, dried 
-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(3-iodophenyl)methanone (93).
Compound 93 was prepared according to procedure VIII using 64 (0.2 g, 0.6 mmol, 1.0 equiv) and 3-iodobenzoic acid (0.2 g, 0.6 mmol, 1.0 equiv). The crude material was subjected to silica gel chromatography (ISCO, RediSep 4 g column, 0− 70% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (mixture of rotamers, 0.2 g, 59%). 1 [
, ′ -B i p h e n y l ] -3 -y l ( 6 , 7 -d i m e t h o x y --( ( 4 -methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)-methanone (94).
Compound 94 was prepared according to procedure VIII using 64 (0.5 g, 1.5 mmol) and 3-phenylbenzoic acid (0.3 g, 1.5 mmol, 1.0 equiv) in DCM (10 mL) and DMF (2.0 mL). The crude yellow residue was purified by silica gel chromatography (ISCO, Silicycle 12 g column, 0−70% EtOAc/ hexanes gradient) to afford the title compound as a white amorphous solid (0.26 g, 34%, mixture of rotamers). 1-(3-(6,7-Dimethoxy-1-((4-methoxyphenoxy)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)ethanone (99). Compound 99 was prepared according to procedure VIII using 64 (1.0 g, 3.0 mmol) and 3-acetylbenzoic acid (0.5 g, 3. 04 mmol, 1.0 equiv) in DCM (10 mL) and DMF (2.0 mL). The crude residue was purified by silica gel chromatography (ISCO, Silicycle 12 g column, 0−70% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (0.32 g, 22%, mixture of rotamers). 1 (3-Bromophenyl)(1-((4-ethoxyphenoxy)methyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methanone (101).
Compound 101 was prepared according to procedure VII using 75 (0.14 g, 0.4 mmol) and 3-bromobenzoyl chloride (0.10 g, 0.5 mmol, 1.2 equiv). The crude material was purified by silica gel chromatography (ISCO, Silicycle 4 g column, 0− 70% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (mixture of two rotamers, 0.1 g, 51%). 1 (1-((4-(Benzyloxy)phenoxy)methyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)(3-chlorophenyl)methanone (109). Compound 109 was prepared according to procedure VII using 72 (0.18 g, 0.44 mmol) and 3-chlorobenzoyl chloride (0.09 g, 0.5 mmol, 1.2 equiv). The crude material was purified by silica gel chromatography (ISCO, RediSep 4 g column, 0− 70% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (mixture of two rotamers, 0.13 g, 52%). hexanes gradient) afforded the title compound as a white amorphous solid (mixture of rotamers, 0.14 g, 73% 153.3, 152.9, 147.2, 146.9, 136.9, 130.1, 129.0, 128.8,  128.0, 127.9, 127.1, 126.8, 125.7, 116.1, 115.9, 115.1, 109.6,  108.9, 107.8, 107.3, 101.5, 71.6, 70.6, 57.8, 56.2, 52.4, 43.2 99 (m, 1H), 3.84−3.71 (m, 10H), 3.35−3.10 (m, 1H) Compound 117 was prepared according to procedure VII using 69 (0.25 g, 0.8 mmol) and 3-chlorobenzoyl chloride (0.18 g, 1 mmol, 1.2 equiv). The crude material was purified by silica gel chromatography (ISCO, RediSep 4 g column, 0−60% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (0.1 g, 27%) . 1 H NMR (CDCl 3 , 400 MHz) δ: 7.61−6.94 (m, 5H), 6 .89−5.98 (m, 6H), 1H [5.15, 4. 87 (dd, J 1 = 3.6 Hz, J 2 = 9.6 Hz; dd, J 1 = 5. 4 Hz, J 2 = 12. 6 Hz)], 4.36 (m, 1H), 1H [4.15, 3.94 (m, m)], 3.81 (s, 3H) , 3.77 (s, 3H), 3.76−3.69 (m, 1H), 3.31−3.14 (m, 1H) 5 .0 equiv) were suspended in EtOH (2.7 mL) and heated to 70°C. The reaction mixture was allowed to stir for 3 h. Upon completion, the reaction was basified to pH 9 with saturated NaHCO 3 . DCM was added, and the mixture was filtered through a silica plug eluting with 10% MeOH/DCM. The organics were separated and washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ISCO, RediSep 25 g column, 10−80% EtOAc/hexanes gradient) to yield the title compound as an off-white amorphous solid (0.09 g, 33%, mixture of rotamers 5 .0 equiv) were suspended in EtOH (5.8 mL) and heated to 70°C. The reaction mixture was allowed to stir for three hours. Upon completion, the reaction was basified to pH 9 with saturated NaHCO 3 . DCM was added, and the mixture was filtered through a silica plug eluting with 10% MeOH/DCM. The organics were separated and washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ISCO, RediSep 40 g column, 10−80% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (0. 21 Compound 130 (0.20 g, 0. 4 mmol, 1.0 equiv) and tin(II) chloride dihydrate (0.4 g, 1.9 mmol, 5.0 equiv) were suspended in EtOH (1.5 mL) and heated to 70°C. The reaction mixture was allowed to stir for 3 h. Upon completion, the reaction was basified to pH 9 with saturated NaHCO 3 . DCM was added, and the mixture was filtered through a silica plug eluting with 10% MeOH/DCM. The organics were separated and washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ISCO, RediSep 25 g column, 10−80% EtOAc/hexanes gradient) to afford the title compound as a brown amorphous solid (0. 13 10 mmol, 5 equiv) were suspended in dry methanol (2.8 mL), and sodium methoxide (0.05 mL, 0.2 mmol, 1 equiv) was added dropwise at 0°C. After the addition was complete, the reaction was heated to reflux. After stirring at reflux for 1 h, the reaction was allowed to cool to room temperature. Sodium borohydride (0.04 g, 1.10 mmol, 5 equiv) was added and the reaction was heated to reflux for 1 additional hour. The reaction was allowed to cool to room temperature, and 1 M NaOH was added. The reaction mixture was extracted with DCM, washed with water and brine, dried with MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ISCO, RediSep 20 g column, 0−80% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (0.07 g, 72% were suspended in dry methanol (5.5 mL), and sodium methoxide (0.10 mL, 0.44 mmol, 1 equiv) was added dropwise at 0°C. After the addition was complete, the reaction was heated to reflux. After 1 h at reflux, the reaction was allowed to cool to room temperature. Sodium borohydride (0.083 g, 2.19 mmol, 5 equiv) was added, and the reaction was heated to reflux for 1 additional hour. The reaction was allowed to cool to room temperature, and 1 M NaOH was added. The reaction mixture was extracted with DCM, washed with water and brine, dried with MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ISCO, RediSep 20 g column, 0−80% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (0. 15 (6,7-Dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-2-yl)methanone (138).
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Compound 138 was prepared according to procedure VII using 64 (0.13 g, 0.4 mmol) and 2-napthoyl chloride (0.09 g, 0.5 mmol). The crude residue was purified by silica gel chromatography (ISCO, RediSep 4 g column, 0−60% EtOAc/hexanes gradient) to afford the title compound as an off-white amorphous solid (mixture of rotamers, 0.04 g, 21%). 1 1-(6,7-Dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-morpholinoethanone (140). Compound 140 was prepared via a two step sequence. Tetrahydroisoquinoline 64 (0.7 g, 2.1 mmol) was dissolved in dry DCM (20 mL) and cooled to 0°C in an ice bath. Triethylamine (0.22 g, 2.1 mmol, 1.0 equiv) was added to the cooled mixture, followed by dropwise addition of chloroacetyl chloride (0.24 g, 2.1 mmol, 1.0 equiv). The reaction was warmed to room temperature and stirred for an additional 2 h. The reaction was quenched with 1 M HCl and extracted into DCM (2×). The combined organics were washed with brine and water, dried over MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ISCO, RediSep 12 g column, 0−60% EtOAc/hexanes gradient) to afford the α-chloro amide (0.67 g, 78%, mixture of rotamers) as a white amorphous solid. (6,7-Dimethoxy-1-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)(3-fluorophenyl)methanone (154). Compound 154 was prepared via procedure VII using 153 (0.8 g, 3.0 mmol) and 3-fluorobenzoyl chloride (0.6 g, 3.0 mmol). The crude material was purified by silica gel chromatography (ISCO, RediSep 12 g column, 0−60% EtOAc/hexanes gradient) to afford the title compound as a white amorphous solid (0.8 g, 71%, mixture of rotamers). 1 (6,7-Dimethoxy-1-(4-methoxyphenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)methanone (160). Compound 160 was prepared according to procedure VII using 150 (0.20 g, 0.6 mmol) and benzoyl chloride (0.10 g, 0.73 mmol, 1.2 equiv). The crude material was purified by silica gel chromatography (ISCO, RediSep 4 g column, 0−60% EtOAc/hexanes gradient) to afford the title compound as an off-white amorphous solid (0.10 g, 38%, mixture of rotamers). 1 H NMR (CDCl 3 , 400 MHz) δ: 7.43−7.32 (m, 5H), 2H [7.18, 6.94 
